• About us
• Contact

Advertisement

Organisation › Details

Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. *

 

	Start	2001-01-01 established
	Industry	BIOTECH
	Industry 2	Nanobodies® (Ablynx)
	Person	Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry)
	Person 2	Heylen, Johan (Ablynx 201411– CCO before GSK + Servier + Wyeth)
	Region	Zwijnaarde
	Country	Belgium
	Street	21 Technologiepark
	City	9052 Zwijnaarde
	Tel	+32-9-262-0000
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	85,187,000 (income, total (2016) 2016-12-31)
	Profit	-1,087,000 (2016-12-31)
	Cash	208,600,000 (2017-09-30)
		* Document for »About Section«: Ablynx N.V.. (7/20/17). "Press Release: Ablynx and Sanofi Enter into a Strategic Collaboration to Develop Nanobody Product Candidates Focused on Immune-mediated Inflammatory Diseases". Ghent.
		Record changed: 2024-02-12

Advertisement

More documents for Sanofi (Group) [since May 2011]

• [1] Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris....
• [2] CureVac N.V.. (1/10/23). "Press Release: CureVac Appoints Alexander Zehnder as CEO from April 1, 2023". Mainz & London....
• [3] Corteria Pharmaceuticals SAS. (12/9/21). "Press Release: Corteria Pharmaceuticals Announces Closing of €12M Seed Financing to Advance Portfolio Assets". Paris....
• [4] Hyloris Pharmaceuticals S.A.. (2/3/21). "Press Release: Hyloris Appoints Marieke Vermeersch as VP of Investor Relations and Corporate Communications". Liège....
• [5] Kiadis Pharma N.V.. (11/2/20). "Press Release: Sanofi Offers to Acquire Kiadis for €308 Million". Paris & Amsterdam....
• [6] Lava Therapeutics B.V.. (9/17/20). "Press Release: Lava Therapeutics Announces $83 Million Series C Financing to Advance Novel Immuno-Oncology Programs". Utrecht & Philadelphia, PA....
• [7] Kiadis Pharma N.V.. (7/8/20). "Press Release: Kiadis Licenses Previously Undisclosed Pre-clinical K-NK-cell Programs to Sanofi, with Total Potential Deal Value of €875 Million, plus Royalties". Amsterdam....
• [8] GlaxoSmithKline plc. (4/14/20). "Press Release: Sanofi and GSK to Join Forces in Unprecedented Vaccine Collaboration to Fight COVID-19". London....
• [9] Affimed N.V.. (3/17/20). "Press Release: Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer". Heidelberg....
• [10] Silence Therapeutics plc. (8/5/19). "Press Release: Silence Therapeutics Appoints Jørgen Wittendorff as Head of Manufacturing". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.